Faculty of Pharmacy and Biochemistry, University of Zagreb, 10000 Zagreb, Croatia.
Acta Pharm. 2011 Mar;61(1):1-14. doi: 10.2478/v10007-011-0006-6.
In the last few years, various studies have been providing evidence that metal ions are critically involved in the pathogenesis of major neurological diseases (Alzheimer, Parkinson). Metal ion chelators have been suggested as potential therapies for diseases involving metal ion imbalance. Neurodegeneration is an excellent target for exploiting the metal chelator approach to therapeutics. In contrast to the direct chelation approach in metal ion overload disorders, in neurodegeneration the goal seems to be a better and subtle modulation of metal ion homeostasis, aimed at restoring ionic balance. Thus, moderate chelators able to coordinate deleterious metals without disturbing metal homeostasis are needed. To date, several chelating agents have been investigated for their potential to treat neurodegeneration, and a series of 8-hydroxyquinoline analogues showed the greatest potential for the treatment of neurodegenerative diseases.
在过去的几年中,各种研究都提供了证据表明金属离子在主要神经疾病(阿尔茨海默病、帕金森病)的发病机制中起着至关重要的作用。金属离子螯合剂被认为是治疗涉及金属离子失衡的疾病的潜在疗法。神经退行性变是利用金属螯合剂治疗方法的一个极好的靶点。与金属离子过载疾病中的直接螯合方法不同,在神经退行性变中,目标似乎是更好地、更微妙地调节金属离子的动态平衡,旨在恢复离子平衡。因此,需要能够协调有害金属而不干扰金属动态平衡的适度螯合剂。迄今为止,已经研究了几种螯合剂来评估它们治疗神经退行性变的潜力,一系列 8-羟基喹啉类似物显示出治疗神经退行性疾病的最大潜力。